within Pharmacolibrary.Drugs.ATC.J;

model J01MA18
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00012183333333333333,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0156,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.008400000000000001,
    k12             = 11.2,
    k21             = 11.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01MA18</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pazufloxacin is a fluoroquinolone antibiotic, primarily used for the treatment of bacterial infections such as respiratory tract infections, urinary tract infections, and intra-abdominal infections. It is mainly used in Japan and some other Asian countries and is not widely approved in the US or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult male volunteers after single intravenous administration.</p><h4>References</h4><ol><li><p>Lee, J, et al., &amp; Yoon, YR (2012). Single-dose pharmacokinetics and dose proportionality of intravenous pazufloxacin mesilate in healthy Korean volunteers. <i>Expert opinion on drug metabolism &amp; toxicology</i> 8(8) 921–928. DOI:<a href=\"https://doi.org/10.1517/17425255.2012.688951\">10.1517/17425255.2012.688951</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22809012/\">https://pubmed.ncbi.nlm.nih.gov/22809012</a></p></li><li><p>Uegami, S, et al., &amp; Sueda, T (2014). Pharmacokinetics and pharmacodynamic target attainment of intravenous pazufloxacin in the bile of patients undergoing biliary pancreatic surgery. <i>Journal of chemotherapy (Florence, Italy)</i> 26(5) 287–292. DOI:<a href=\"https://doi.org/10.1179/1973947814Y.0000000167\">10.1179/1973947814Y.0000000167</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24552254/\">https://pubmed.ncbi.nlm.nih.gov/24552254</a></p></li><li><p>Nakamura, K, et al., &amp; Sumitomo, M (2017). Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis. <i>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</i> 23(12) 809–813. DOI:<a href=\"https://doi.org/10.1016/j.jiac.2017.08.005\">10.1016/j.jiac.2017.08.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28923301/\">https://pubmed.ncbi.nlm.nih.gov/28923301</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01MA18;
